Human-caused Phenomenon or Process
FDA Delays Reviews for Eli Lilly, Sanofi, and Others in New Priority Voucher Program Due to Safety and Efficacy Concerns
FDA delays; Eli Lilly; Sanofi; voucher program; orforglipron; Tzield; safety concerns; efficacy issues
Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
Antengene; JPM Conference; ATG-022; ADCs; TCEs; AnTenGager; ATG-125; ATG-207
FDA Commissioner Makary Addresses COVID-19 Vaccine Safety Concerns Amid Internal Debates and Investigations
Marty Makary; FDA; COVID-19 vaccine; myocarditis; vaccine deaths; safety warnings; RFK Jr.; mRNA vaccines
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial on December 3, 2025
ADC Therapeutics; LOTIS-7; clinical trial update; ZYNLONTA; Phase 1b trial; loncastuximab tesirine; safety; efficacy; corporate webcast
Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update
Rakovina Therapeutics; Q3 2025; financial results; net loss; research and development expenses; AI-powered drug discovery; ATR inhibitor; CNS penetration; corporate milestones; NanoPalm joint-venture; investment conference; DTC eligibility
GSK and AnaptysBio Enter Legal Dispute Over Jemperli License Amid Allegations of Contract Breaches
GSK; AnaptysBio; Jemperli; dostarlimab; TESARO; litigation; license agreement; oncology; royalties; endometrial cancer
Metsera Calls Pfizer’s Threats ‘Nonsense’ as Rift Between Companies Widens
Metsera; Pfizer; Novo Nordisk; merger dispute; litigation; obesity drug acquisition; regulatory approval; Delaware Court of Chancery
AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability
AH-001; AI-designed drug; Phase I clinical trial; safety; tolerability; androgenetic alopecia; protein degrader; AnHorn Medicines; generative AI; hair loss
Intellia Pauses Two CRISPR Trials After Severe Liver Toxicity Hospitalizes Patient
Intellia Therapeutics; CRISPR; transthyretin amyloidosis; Phase III trials; gene editing; liver toxicity; patient hospitalization; safety pause
Halda’s HLD-0915 Shows Promising First-in-Human Results as a Safer RIPTAC Cancer Therapeutic
Halda Therapeutics; HLD-0915; RIPTAC; metastatic castration-resistant prostate cancer; first-in-human; safety; anti-tumor activity; oral therapeutic